Recommendations for Screening and Diagnosis of Chagas Disease in the United States

Background Chagas disease affects an estimated 326 000-347 000 people in the United States and is severely underdiagnosed. Lack of awareness and clarity regarding screening and diagnosis is a key barrier. This article provides straightforward recommendations, with the goal of simplifying identification and testing of people at risk for US healthcare providers. Methods A multidisciplinary working group of clinicians and researchers with expertise in Chagas disease agreed on 6 main questions, and developed recommendations based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, after reviewing the relevant literature on Chagas disease in the United States. Results Individuals who were born or resided for prolonged time periods in endemic countries of Mexico and Central and South America should be tested for Trypanosoma cruzi infection, and family members of people who test positive should be screened. Women of childbearing age with risk factors and infants born to seropositive mothers deserve special consideration due to the risk of vertical transmission. Diagnostic testing for chronic T. cruzi infection should be conducted using 2 distinct assays. Conclusions Increasing provider-directed screening for T. cruzi infection is key to addressing this neglected public health challenge in the United States. This article provides recommendations for screening and diagnosis of Chagas disease in the United States, including identification of the population at risk in community or clinical settings, diagnosis of chronic and congenital infection, and next steps following confirmed diagnosis.

Automated summary

This article provides straightforward recommendations for the screening and diagnosis of Chagas disease in the United States. The study emphasizes the importance of testing individuals who were born or resided in endemic countries of Mexico and Central and South America, as well as screening family members of those who test positive. Special consideration should also be given to women of childbearing age with risk factors and infants born to seropositive mothers.